Using bi-transgenic TRAMP mouse models of prostate cancer, soluble MICB was shown to promote carcinoma progression by depleting peripheral NK cells, whereas membrane-restricted MICB supported long-term tumor-free survival through sustained NKG2D-mediated anti-tumor immunity [40]. The gene discussed is KLRK1; the disease is neoplasm.